IL-LANIFICIO
Il Lanificio, the premium Italian apparel brand, is pleased to announce that it is opening two new stores in Pescara, Italy and Aubonne, Switzerland. These new openings will increase Il Lanificio’s total portfolio to 18 stores across Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240605960836/en/
The Pescara store will open on 7 June, with the Swiss store due to open in July, marking Il Lanificio’s third international outlet, joining existing locations in San Marino and Mendrisio, Switzerland and emphasising the brand's growing European presence.
Il Lanificio is a premium Italian apparel brand for men and women, known for its high-quality fabrics, exceptional tailoring and its commitment to deliver specialist, Italian craftsmanship direct to customers. The brand blends tradition with contemporary style, offering collections that cater to all demographics across outlets and online retail platforms. The new stores will be versatile, light and authentic, designed to embrace the customer with a warm welcome and communicate the quality and authenticity of its products. A new, multi-language e-commerce platform completes the customer omnichannel experience.
Since being acquired in 2018 by Njord Partners, Il Lanificio has benefitted from a renewed focus on its outlet business and an ambitious growth plan. Last year the Company grew its number of stores by 60% and its revenues by 40%. Il Lanificio intends to open up to 10 further stores in Europe by the end of 2025.
Filippo Vadda, CEO of Il Lanificio, commented: “Il Lanificio is internationally recognized as a high-quality apparel brand and the opening of these new stores underlines our commitment to growth both in Italy and internationally. We have doubled our number of outlets since 2021 and are excited to continue this expansion across Europe as we target the opening of six new stores this year, showcasing the best of our made-in-Italy offerings”.
Arvid Trolle, Partner at Njord Partners, said: “We are very pleased to see Il Lanificio go from strength to strength as an influential and growing apparel brand. Njord recognized the heritage and potential of the Il Lanificio brand and we are delighted that our investment in the business has ensured the sustainability and growth of the business. The company's performance and expansion are testament to the hard work and dedication of Il Lanificio’s team and we are excited by the promising future that lies ahead for us all.”
About Il Lanificio
Il Lanificio is an Italian outlet apparel brand of luxury made-in-Italy products. It is recognised by customers for having one of the best price-to-quality offers in the casual-chic and formal market. The first Il Lanificio retail store opened in 2002, and now has 15 stores across Italy, two in Switzerland and one in San Marino. Il Lanificio continues to grow whilst remaining focused on traditional design and excellent quality.
To find out more visit: https://www.illanificio.it/en/
About Njord Partners
Njord Partners is a special situations investment manager and provider of long-term flexible capital solutions. Established in 2013, Njord Partners manages capital in excess of €1 billion. Investing in European middle-market companies facing complex situations, its mission is to deliver superior risk-weighted returns to investors while preserving capital. As a capital partner, Njord Partners offers flexible debt and equity solutions, actively facilitating strategic and operational enhancements within its portfolio companies to drive value.
To find out more visit: https://njordpartners.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240605960836/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Media Release: Allianz lifts financial ambitions at its Capital Markets Day 202410.12.2024 07:07:00 CET | Press release
Allianz introduces four new ambitious Group financial targets for the 2024-2027 period:Earnings per share CAGR of 7-9 percent1Return on equity of at least 17 percent2Solvency II operating capital generation of 24-25 percentage points in 20273Cumulative net cash remittance of more than 27 billion euros in the years 2025-2027Allianz commits to an attractive total payout ratio of at least 75 percent on average4Having built the foundation to deliver growth at scale, Allianz continues its resilient value creation with three levers: smart growth, reinforced productivity, and strengthened resilienceA flight to trust, accelerated by secular trends, is fuelling greater demand for innovative Protection and Retirement solutions. Through thoughtful portfolio design, Allianz is prepared to capitalize on its role to protect and grow its customers’ most valuable assetsAllianz’s high trust levels and its continued focus on enhancing the customer relationship create a pull effect for Allianz’s products
Sirius Therapeutics Announces Promising Phase I Clinical Data from Its Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders10.12.2024 05:00:00 CET | Press release
Data presented at American Society of Hematology annual meeting Sirius Therapeutics today announced promising preliminary data from its Phase 1 first-in-human clinical trial of SRSD107, a next generation siRNA therapeutics under clinical development for the prevention and treatment of thromboembolic disorders, such as myocardial infarction, ischemic stroke, and venous thromboembolism. The trial data were presented during a poster session at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held in San Diego, CA. SRSD107 is designed to inhibit Factor XI (FXI), a protein in the coagulation pathway that has shown potential to reduce thrombosis without significantly increasing the risk of bleeding, a major liability of current drugs. “In this trial, SRSD107 was safe and well tolerated, with pharmacokinetic parameters consistent with a typical siRNA product,” said Dr. Patrick Yue, Sirius’ Chief Medical Officer. “We are encouraged by the marked, prolonged reduction
Mori Memorial Foundation Issues GPCI–2024 and GPCI–Financial Centers Reports:10.12.2024 04:00:00 CET | Press release
— Post-Pandemic Economic Recovery and International Tourism Expansion Impact Rankings — The Mori Memorial Foundation’s Institute for Urban Strategies, a research body established by Mori Building, Tokyo’s leading urban landscape developer, today released its Global Power City Index (GPCI) 2024 report on the overall strength of the world’s 48 major cities. For the second time, the report additionally includes the 'GPCI–Financial Centers' index. This index reflects the growing importance of measures taken by major cities to enhance their status as international financial centers, capturing changes in their financial and business environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241209714811/en/ The 48 major cities evaluated in Mori Memorial Foundation’s GPCI–2024 Report (Graphic: Business Wire) More than 18 months have elapsed since the World Health Organization declared an end to the COVID-19 pandemic in May 2023.
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets10.12.2024 02:30:00 CET | Press release
5-year follow-up from SEQUOIA study demonstrated treatment with BRUKINSA reduced the risk of progression or death by 71% compared to bendamustine-rituximab in patients with treatment-naïve CLL, further solidifying its position as the leader in new patient starts in both frontline and relapsed/refractory (R/R) CLL with the broadest label of any BTK inhibitorAt a median follow-up of 1.5 years, promising data from the 320 mg expansion cohort of phase 1/1b study shows no progression in patients with treatment-naïve CLL treated with sonrotoclax, a next-generation BCL2 inhibitor, in combination with BRUKINSA highlighting the potential of this fixed-duration, oral-only combination as a best-in-disease optionData for BTK degrader BGB-16673 from phase 1/2 study highlight its potential in both treatment-resistant CLL and other B-cell malignancies representing high unmet needs BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that plans to change its name to BeOne
Material Receives Splash Award for Outstanding Drupal Website10.12.2024 02:00:00 CET | Press release
– Exceptional client work with INSEAD demonstrates noteworthy innovation and impact in digital engagement solutions – Material, a leading insights, marketing and technology company, is pleased to announce it is the recipient of the Splash Award in the “Education” category for work with INSEAD – The Business School for the World® and runner-up in the “Corporate” category for work with Stuff Limited. The first-ever DrupalCon Singapore Splash Awards celebrate outstanding websites and digital experiences built with Drupal, highlighting the creativity, technical excellence and innovative solutions agencies and developers bring to diverse industries and challenges. For the award-winning “Education” work, Material partnered with INSEAD to enhance the school’s overall digital presence, improve engagement and strengthen brand identity, aligning technology with business strategy to drive growth and success. Leveraging the latest Drupal technology, Material helped INSEAD increase conversion and r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom